Genistein, Resveratrol, and 5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside Induce Cytochrome P450 4F2 Expression through an AMP-Activated Protein Kinase-Dependent Pathway

Activators of AMP-activated protein kinase (AMPK) increase the expression of the human microsomal fatty acid ω-hydroxylase CYP4F2. A 24-h treatment of either primary human hepatocytes or the human hepatoma cell line HepG2 with 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR), which is converted to 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranosyl 5′-monophosphate, an activator of AMPK, caused an average 2.5- or 7-fold increase, respectively, of CYP4F2 mRNA expression but not of CYP4A11 or CYP4F3, CYP4F11, and CYP4F12 mRNA. Activation of CYP4F2 expression by AICAR was significantly reduced in HepG2 cells by an AMPK inhibitor, 6-[4-(2-piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine (compound C) or by transfection with small interfering RNAs for AMPKα isoforms α1 and α2. A 2.5-fold increase in CYP4F2 mRNA expression was observed upon treatment of HepG2 cells with 6,7-dihydro-4-hydroxy-3-(2′-hydroxy[1,1′-biphenyl]-4-yl)-6-oxo-thieno[2,3-b]pyridine-5-carbonitrile (A-769662), a direct activator for AMPK. In addition, the indirect activators of AMPK, genistein and resveratrol increased CYP4F2 mRNA expression in HepG2 cells. Pretreatment with compound C or 1,2-dihydro-3H-naphtho[2,1-b]pyran-3-one (splitomicin), an inhibitor of the NAD+ activated deacetylase SIRT1, only partially blocked activation of CYP4F2 expression by resveratrol, suggesting that a SIRT1/AMPK-independent pathway also contributes to increased CYP4F2 expression. Compound C greatly diminished genistein activation of CYP4F2 expression. 7H-benz[de]benzimidazo[2,1-a]isoquinoline-7-one-3-carboxylic acid acetate (STO-609), a calmodulin kinase kinase (CaMKK) inhibitor, reduced the level of expression of CYP4F2 elicited by genistein, suggesting that CaMKK activation contributed to AMPK activation by genistein. Transient transfection studies in HepG2 cells with reporter constructs containing the CYP4F2 proximal promoter demonstrated that AICAR, genistein, and resveratrol stimulated transcription of the reporter gene. These results suggest that activation of AMPK by cellular stress and endocrine or pharmacologic stimulation is likely to activate CYP4F2 gene expression.

[1]  Steven N. Hart,et al.  A Comparison of Whole Genome Gene Expression Profiles of HepaRG Cells and HepG2 Cells to Primary Human Hepatocytes and Human Liver Tissues , 2010, Drug Metabolism and Disposition.

[2]  J. Auwerx,et al.  Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. , 2010, Cell metabolism.

[3]  D. Hardie,et al.  Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. , 2010, Biochimica et biophysica acta.

[4]  M. Rieder,et al.  CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant , 2009, Molecular Pharmacology.

[5]  J. Corral,et al.  Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. , 2009, Blood.

[6]  B. Viollet,et al.  AMP‐activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives , 2009, Acta physiologica.

[7]  R. Tukey,et al.  Opposing Roles of Peroxisome Proliferator-activated Receptor α and Growth Hormone in the Regulation of CYP4A11 Expression in a Transgenic Mouse Model* , 2009, The Journal of Biological Chemistry.

[8]  T. Nakayama,et al.  A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men. , 2009, Molecular genetics and metabolism.

[9]  T. Nakayama,et al.  A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. , 2008, American journal of hypertension.

[10]  R. Magnusson,et al.  Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies. , 2008, Archives of biochemistry and biophysics.

[11]  G. Lippi,et al.  The V433M Variant of the CYP4F2 Is Associated With Ischemic Stroke in Male Swedes Beyond Its Effect on Blood Pressure , 2008, Hypertension.

[12]  G. Labbe,et al.  Drug‐induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies , 2008, Fundamental & clinical pharmacology.

[13]  Fan Lan,et al.  SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase* , 2008, Journal of Biological Chemistry.

[14]  J. Hardwick Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. , 2008, Biochemical pharmacology.

[15]  J. Hodgson,et al.  A Single Nucleotide Polymorphism in the CYP4F2 but not CYP4A11 Gene Is Associated With Increased 20-HETE Excretion and Blood Pressure , 2008, Hypertension.

[16]  Y. Turpaz,et al.  CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.

[17]  R. Magnusson,et al.  Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11 Published, JLR Papers in Press, December 7, 2007. , 2008, Journal of Lipid Research.

[18]  In-kyu Lee,et al.  Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase–Dependent Regulation of the Orphan Nuclear Receptor SHP , 2008, Diabetes.

[19]  B. Viollet,et al.  Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein Kinase* , 2007, Journal of Biological Chemistry.

[20]  M. Rieder,et al.  Functional polymorphism in human CYP4F2 decreases 20-HETE production. , 2007, Physiological genomics.

[21]  Eric F. Johnson,et al.  Regulation of Human Cytochrome P450 4F2 Expression by Sterol Regulatory Element-binding Protein and Lovastatin* , 2007, Journal of Biological Chemistry.

[22]  Eric F. Johnson,et al.  Human Cytochrome P450 Family 4 Enzymes: Function, Genetic Variation and Regulation , 2007, Drug metabolism reviews.

[23]  B. Viollet,et al.  Stimulation of AMP-Activated Protein Kinase Is Essential for the Induction of Drug Metabolizing Enzymes by Phenobarbital in Human and Mouse Liver , 2006, Molecular Pharmacology.

[24]  C. Huard,et al.  Inhibition of Gluconeogenesis through Transcriptional Activation of EGR1 and DUSP4 by AMP-activated Kinase* , 2006, Journal of Biological Chemistry.

[25]  R. Wanders,et al.  Identification of the cytochrome P450 enzymes responsible for the ω‐hydroxylation of phytanic acid , 2006, FEBS letters.

[26]  R. Wanders,et al.  Omega-oxidation of very long-chain fatty acids in human liver microsomes. Implications for X-linked adrenoleukodystrophy. , 2006, The Journal of biological chemistry.

[27]  J. Ha,et al.  Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. , 2005, Biochemical and biophysical research communications.

[28]  R. Roman,et al.  Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. , 2005, Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.

[29]  T. Osborne,et al.  Soy Isoflavones Affect Sterol Regulatory Element Binding Proteins (SREBPs) and SREBP-Regulated Genes in HepG2 Cells 1,2 , 2004 .

[30]  Yu Hong,et al.  AMP-activated Protein Kinase Regulates HNF4α Transcriptional Activity by Inhibiting Dimer Formation and Decreasing Protein Stability* , 2003, Journal of Biological Chemistry.

[31]  Hitoshi Shimano,et al.  Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes DOI 10.1194/jlr.M100417-JLR200 , 2002, Journal of Lipid Research.

[32]  H. Yamashita,et al.  Mechanism for Fatty Acid “Sparing” Effect on Glucose-induced Transcription , 2002, The Journal of Biological Chemistry.

[33]  D. Gottschling,et al.  Identification of a small molecule inhibitor of Sir2p , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Falck,et al.  The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. , 2001, Biochemical and biophysical research communications.

[35]  T. Leff AMP-activated protein kinase regulates gene expression by direct phosphorylation of nuclear proteins. , 2001, Biochemical Society transactions.

[36]  P. Wilson,et al.  Formation of 20-Hydroxyeicosatetraenoic Acid, a Vasoactive and Natriuretic Eicosanoid, in Human Kidney , 2000, The Journal of Biological Chemistry.

[37]  M. Vincent,et al.  Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP‐activated protein kinase , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  C. Lang,et al.  Sepsis and AMPK Activation by AICAR Differentially Regulate FoxO-1, -3 and -4 mRNA in Striated Muscle. , 2008, International journal of clinical and experimental medicine.

[39]  J. Reddy,et al.  Peroxisomal lipid metabolism. , 1994, Annual review of nutrition.